Form 4 filed Nov 9. Every line of the filing.

Form 4 filed Nov 12. Every line of the filing.

Form 4 filed Nov 13. Every line of the filing.

AIM ImmunoTech (NYSE American: AIM) will participate in the Webull Corporate Connect Webinar Series on November 12, 2026. Chief Executive Officer Thomas K. Equels will present during the virtual event, with the live webcast scheduled for 2:40 PM ET.

Form 4 filed Nov 10. Every line of the filing.

O CEO da AIM ImmunoTech comprou ações da empresa por US$ 3.166.

Form 4 filed Nov 6. Every line of the filing.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Click to view the official SEC document.

Form 4 filed Oct 26. Every line of the filing.

Form 4 filed Oct 23. Every line of the filing.

AIM ImmunoTech (AIM) highlighted recent media coverage examining its investigational drug Ampligen’s potential antiviral and post-viral therapeutic applications.Healthcare Business Today featured CEO Tom Equels discussing preparedness for viral outbreaks, while MediTech Today examined AIM’s Long COVID patent protection. AIM describes Ampligen’s possible applications as including emerging viral threats such as Ebola Virus Disease and post-viral conditions. Ampligen is also being studied in the company’s oncology clinical program, which focuses on pancreatic cancer.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Reported Tuesday, Sep 22 - 8:57am EDT (TheFly subscription required to read more.)

Click to view the official SEC document.

Click to view the official SEC document.

Click to view the official SEC document.

AIM ImmunoTech (AIM) announced expanded patent protection for its drug Ampligen in the treatment of Long COVID across major European markets and the United Kingdom, with coverage expected to run through June 2041.The protection consists of three forms of patents in Europe and the UK that became final after a nine‑month opposition period under the European Patent Convention closed on August 25, 2026, with no opposition filed. This follows a newly issued U.S. patent covering Ampligen in combination with pembrolizumab for cancer treatment, broadening Ampligen’s global intellectual property estate across multiple therapeutic areas.The granted claims cover therapeutic double stranded RNA for treating Long COVID, including specific dosing regimens and intranasal, intravenous and inhalation administration, with Ampligen included in this scope. The company reports that Ampligen has undergone extensive clinical and preclinical testing in more than 1,200 patients receiving over 100,000 doses, with no drug-related deaths and favorable safety profiles across several routes of administration.

Reported Monday, Aug 31 - 8:59am EDT (TheFly subscription required to read more.)

AIM ImmunoTech (NYSE American: AIM) announced its participation in the Virtual Investor “Why Now” on‑demand conference, where CEO Thomas Equels presented the company’s investment thesis and clinical progress. The webcast highlights advancement of Ampligen in the Phase 2 DURIPANC trial for metastatic pancreatic cancer, including completion of enrollment ahead of schedule, dosing of the final patient, and the planned transition to primary endpoint evaluation in Q4 2026, with topline results expected in Q1 2027. The video webcast is now available for on‑demand viewing.

AIM ImmunoTech dosed the final patient in its Phase 2 pancreatic cancer trial on June 18, ahead of schedule. NovaBridge Biosciences received FDA Fast Track for its gastric cancer bispecific antibody g...

AIM ImmunoTech dosed the final patient in its Phase 2 pancreatic cancer trial on June 18, ahead of schedule. NovaBridge Biosciences received FDA Fast Track for its gastric cancer bispecific antibody g...

AIM ImmunoTech has offered an update on its efforts underway for developing an treatment for long Covid with its drug, Ampligen.